Abstracts Archive - Page 451 of 2607 - ACR Meeting Abstracts

Abstract Number: 0204 • ACR Convergence 2023
Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases
Claire Rempenault¹, Cedric Lukas², Léa Tardivon³, Claire Daien⁴, Bernard G. Combe⁵, Philippe GUILPAIN³ and JACQUES MOREL⁶, ¹Universary Hospital of Montpellier, Montpellier, France, ²CHU Montpellier, Montpellier, France, ³University of Montpellier, Montpellier, France, ⁴University Hospital, Montpellier, France, ⁵Department of Rheumatology, Montpellier University, Montpellier, France, ⁶Protocole thérapeutique immuno-rhumatologie, Montpellier, France
Background/Purpose: Literature data on the increased risk of severe infection regarding hypogammaglobinemia related to RTX in IMID are controversial and sparse. We proposed to evaluate…
Abstract Number: 0208 • ACR Convergence 2023
Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System
Angela Bobak¹, Emely Pimentel¹, Jordan Jackson², Celia Gray³, Hema Srinivasan³, Andrea Berger³ and David Bulbin³, ¹Geisinger Medical Center Internal Medicine Residency, Danville, PA, ²Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, ³Geisinger Health System, Danville, PA
Background/Purpose: PJP is an opportunistic fungus causing significant morbidity and mortality in immunocompromised patients. Guidelines describe PJP PPX indications among non-HIV infected individuals with cancer…
Abstract Number: 0207 • ACR Convergence 2023
Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos¹, Fadi Shehadeh², Markos Kalligeros¹ and Eleftherios Mylonakis³, ¹Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI, ²Houston Methodist Research Institute, Houston, TX, ³Department of Medicine, Houston Methodist Hospital, Houston, TX
Background/Purpose: Available immunosuppressive treatments for autoimmune inflammatory rheumatic diseases (AIRD) might increase the risk for opportunistic infections, such as Pneumocystis jirovecii pneumonia (PJP). Prophylactic trimethoprim-sulfamethoxazole…
Abstract Number: 0202 • ACR Convergence 2023
Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
Tal Gazitt¹, Noa Hayat², Amir Haddad², Joy Feld³, Nili Stein², Idit Lavi², Ilan Feldhamer⁴, Arnon Dov Cohen⁵, Walid Saliba² and Devy Zisman², ¹Carmel Hospital, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel
Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
Abstract Number: 0190 • ACR Convergence 2023
Racial Disparities in Self-reported Extent and Reasons for Nonadherence in SLE
Kai Sun¹, Londyn Robinson², Amanda Eudy³, Jennifer Rogers¹, Rebecca Sadun¹, Lisa Criscione-Schreiber⁴, Jayanth Doss¹ and Megan Clowse⁵, ¹Duke University, Durham, NC, ²University of Minnesota Medical School, Minneapolis, MN, ³Duke University, Raleigh, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is common in SLE and disproportionately affects Black patients. Nonadherence leads to increased hospitalizations, morbidity, and mortality and is a modifiable factor…
Abstract Number: 0215 • ACR Convergence 2023
Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
Erika Biegelmeyer¹, Mariana Freitas de Aguiar¹, Priscila Dias Cardoso Ribeiro¹, Ketty Lysie Libardi Lira Machado², Maria da Penha Gomes Gouveia², Camila Maria Paiva França Telles³, Samuel Elias Basualto Dias³, Natália Sarzi Sartori⁴, Thaís Evelyn Karnopp⁵, Vanessa de Oliveira Magalhães¹, Flávia Maria Matos Melo Campos Peixoto¹, Laiza Hombre Dias², Débora Marques Veghini², Rodrigo Vieira de Rezende⁶, Katia Lino Baptista⁶, Ana Karla Guedes de Melo⁷, Vitor Alves Cruz⁸, Maria Cecília Dias Corrêa⁹, Adriana Maria Kakehasi¹⁰, Rejane Maria Rodrigues de Abreu Vieira¹¹, Valderilio Feijó Azevedo¹², Olindo Assis Martins-Filho¹³, Charlles Heldan de Moura Castro¹, Ricardo Xavier¹⁴, Andréa Teixeira-Carvalho¹³, Viviane Angelina de Souza⁹, Odirlei André Monticelo¹⁵, Marcelo Pinheiro¹⁶, Edgard Torres dos Reis Neto¹, Emilia Sato¹, Gilda Ferreira¹⁷, Gecilmara Pileggi¹⁸, Valeria Valim¹⁹ and Alexandre wagner Silva de Souza²⁰, ¹Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES), Vitória, Brazil, ³Universidade Federal do Amazonas, Manaus, Brazil, ⁴Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Universidade Federal Fluminense, Niterói, Brazil, ⁷Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, Brazil, ⁸Universidade Federal de Goiás, Goiânia, Brazil, ⁹Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil, ¹⁰Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ¹¹Universidade de Fortaleza (UNIFOR), Fortaleza, Brazil, ¹²Department of Internal Medicine, Hospital de Clínicas at the Federal University of Paraná, Curitiba, Paraná, Brazil, ¹³Instituto Renè Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Brazil, ¹⁴Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁵Division of Rheumatology, Department of Internal Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁶UNIFESP/ EPM, São Paulo, Brazil, ¹⁷Federal University of Minas Gerais, Belo Horizonte, Brazil, ¹⁸UNIFESP, Ribeirão Preto, Brazil, ¹⁹Universidade Federal do Espírito Santo, Vitória, Brazil, ²⁰Division of Rheumatology, Medical School, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Vaccine platforms, number of doses, and immunosuppressive drugs can influence the immunogenicity after SARS-CoV-2 vaccination in individuals with immune-mediated rheumatic diseases. Considering the heterogeneity…
Abstract Number: 0214 • ACR Convergence 2023
COVID-19 Vaccine Uptake, Hesitancy, and Flare in a Large Rheumatology Practice Network
Emily Holladay¹, Amy S. Mudano², Fenglong Xie², Patrick Stewart³, Lesley E. Jackson¹, Maria I. ("Maio") Danila⁴, Kelly Gavigan⁵, W. Benjamin Nowell⁶, Shilpa Venkatachalam⁷ and Jeffrey Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Illumination Health, Hoover, AL, ³Illumination Health, Birmingham, AL, ⁴University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶Global Healthy Living Foundation, Nyack, NY, ⁷Global Healthy Living Foundation, New York, NY
Background/Purpose: COVID-19 vaccine uptake in autoimmune and inflammatory rheumatic disease (AIIRD) patients is an area of concern to rheumatologists and other providers. These patients are…
Abstract Number: 0205 • ACR Convergence 2023
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
Jamie Chieh Lo¹, Ying-Nan Tsai², Cheng-Hao Tseng³, Yao-Chun Hsu⁴ and Song-Chou Hsieh⁵, ¹School of Medicine, I-Shou University, Kaohsiung, Taiwan, ²Department of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ³Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ⁴I-Shou University School of Medicine, E-Da Hospital Center of Liver Diseases, Kaohsiung, Taiwan, ⁵National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Chronic hepatitis C virus (HCV) infection is associated with autoimmune extrahepatic manifestations including increased production of autoantibodies such as rheumatoid factor (RF). Prior to…
Abstract Number: 0218 • ACR Convergence 2023
Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases
Yumeko Kawano¹, Xiaosong Wang¹, Naomi Patel², Grace Qian¹, Emily Kowalski¹, Katarina Bade³, Kathleen Vanni¹, Accelerating Medicines Partnership (AMP): RA/SLE¹, Zachary Williams², Claire Cook², Shruthi Srivatsan², Zachary Wallace⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: During the height of the COVID-19 pandemic in the United States, tixagevimab/cilgavimab (Evusheld), a combination of monoclonal antibodies directed against the SARS-CoV2 spike protein,…
Abstract Number: 0221 • ACR Convergence 2023
Post-COVID-19 Autoimmune Serologies and Immunophenotypes
Emily G. Oakes¹, Katherine Buhler², Ifeoluwakiisi Adejoorin¹, Kathryne Marks¹, Eilish Dillon¹, Jack Ellrodt¹, Jeong Yee¹, Deepak Rao¹, May Choi³ and Karen Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²University of Calgary; Cumming School of Medicine, Calgary, AB, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Autoimmunity after COVID-19 infection has been reported. We examined connective tissue disease (CTD) symptoms and autoantibodies, SARS-CoV-2 serologies, and T and B cell immunophenotypes…
Abstract Number: 0216 • ACR Convergence 2023
High Immunogenicity of mRNA Covid-19 Vaccine Booster in Immune Mediated Inflammatory Disease
Rebecca Haberman¹, Rebecca Blank², Paula Rackoff², Gary Solomon³, Samrachana Adhikari¹, Natalie Azar⁴, Ramin Herati¹, Pamela Rosenthal⁵, Peter Izmirly⁶, Jonathan Samuels⁷, Brian Golden⁸, Soumya Reddy⁵, Mark Mulligan¹ and Jose Scher⁶, ¹NYU Grossman School of Medicine, New York, NY, ²New York University, New York, NY, ³NYU Langone School of Medicine, Hartsdale, NY, ⁴NYU Langone, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷NYU Langone, Rye Brook, NY, ⁸NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Patients with immune-mediated inflammatory disorders (IMIDs) have an inherently heightened susceptibility to infection and may be considered high risk for COVID-19, yet IMID populations…
Abstract Number: 0197 • ACR Convergence 2023
Development of a Chikungunya Arthritis Disease Activity Score
Aileen Chang¹, Samuel Simmens¹, Hugh Watson², Richard Amdur³, Andre Siqueira⁴, Abigale Proctor¹, Sarah Tritsch¹, Carlos Herrera¹, Liliana Encinales⁵, Alfonso Sucerquia¹, Alejandro Jaller¹, Juan Jose Jaller⁶, Kennedy Amaral⁷, Gary Simon¹, Larry Moreland⁸, Andres Cadena⁹ and Gary Firestein¹⁰, ¹George Washington University, Washington, DC, ²Evotec, Lyon, France, ³Northwell, Washington, DC, ⁴Fiocruz, Rio, Brazil, ⁵Allied Research Society, Barranquilla, Colombia, ⁶Reumatologos SAS, Barranquilla, Colombia, ⁷Institute of Diagnostic Medicine of Cariri, Pernambuco, Brazil, ⁸University of Colorado, Denver, CO, ⁹Clinica de la Costa, Barranquilla, Colombia, ¹⁰University of California San Diego, San Diego, CA
Background/Purpose: Chikungunya virus is an alphavirus spread by mosquitos that causes a debilitating chronic arthritis that has no standard treatment to date. The objective of…
Abstract Number: 0196 • ACR Convergence 2023
Limited Regulatory T Cell Response in Post-Chikungunya Viral Arthritis: A Therapeutic Opportunity?
Aileen Chang¹, Sarah Tritsch¹, Carlos Herrera¹, Liliana Encinales², Andres Cadena³, Wendy Rosales⁴, Evelyn Mendoza⁵, Samuel Simmens¹, Richard Amdur⁶, Paige Fierbaugh¹, Abigale Proctor¹, Alfonso Sucerquia¹, Christopher Mores¹, David Boyle⁷, Gary Firestein⁷ and Gary Simon¹, ¹George Washington University, Washington, DC, ²Allied Research Society, Barranquilla, Colombia, ³Clinica de la Costa, Barranquilla, Colombia, ⁴Universidad Libre, Barranquilla, Colombia, ⁵Universidad Libre, Bogotá, Colombia, ⁶Northwell, Washington, DC, ⁷University of California San Diego, San Diego, CA
Background/Purpose: The objective was to define the relationship between chronic chikungunya (CHIKV) post-viral arthritis disease severity, interleukin (IL)-2, and T cell subsets in order to…
Abstract Number: 0200 • ACR Convergence 2023
Herpes Zoster Prevalence in Patients with Rheumatic Diseases
Rodrigo J. Castillo-de la Garza¹, Jorge A. Esquivel-Valerio², Emmanuel Campos-Tinajero², Anahí Carrazco Chapa³, Gisela García Arellano⁴, Axel A. De Leon-Perez², Pablo Gamez-Siller² and Dionicio A. Galarza-Delgado⁵, ¹Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ³Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose: Herpes zoster (HZ) is a painful rash that is commonly known as shingles. People that had a primary infection caused by the varicella-zoster virus…
Abstract Number: 0137 • ACR Convergence 2023
Incidence of and Risk Factors for Myelodysplastic Syndromes in Patients with Rheumatologic Diseases
YoungEun Kim¹, Hansun Song¹, Wook Jang Seo², Jinseok Kim³, Soo Min Ahn¹, Seokchan Hong⁴, Ji-Seon Oh⁵, Chang-Keun Lee⁶, Bin Yoo⁶ and Yong-Gil Kim¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ²Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea, ³Department of Rheumatology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju-si, Jeju-do, South Korea, La Jolla, CA, South Korea, ⁴Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ⁵Department of Information Medicine, Big Data Research Center, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, South Korea, ⁶Asan Medical Center, Seoul, South Korea
Background/Purpose: Myelodysplastic syndrome (MDS) is a hematologic disorder characterized by dysplasia of bone marrow, leading to ineffective hematopoiesis and cytopenia. Despite sporadic reports of associations…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].